Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL17P8 (Ribosomal protein L17 pseudogene 8) is a processed pseudogene in the human genome[1]. Pseudogenes are non-functional segments of DNA that resemble functional genes but do not encode functional proteins. RPL17P8 is derived from the ribosomal protein L17 (RPL17) gene but lacks coding potential, and there is no evidence that it produces a functional protein or acts as a therapeutic target. The RPL17 gene itself encodes a core component of the large 60S ribosomal subunit involved in protein synthesis[3], but RPL17P8 is only a noncoding genomic relic. There are no known disease associations, biomarkers, therapeutic drugs, or mechanisms of action involving this pseudogene.\n\nNote:\n- The designation \"pseudogene\" indicates it is not an active gene product, receptor, enzyme, or druggable target.\n- There is no evidence in current genomic or drug databases indicating that RPL17P8 plays a regulatory or functional role in humans[1][9].\n- If a functional molecule or gene is intended, RPL17 (Ribosomal protein L17, functional gene) could be relevant, but RPL17P8 is not a relevant target for therapeutic or diagnostic purposes[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L17 pseudogene 8 (RPL17P8).